Takeda appoints Hernán Porcile as Head of the EAMEA region, continuing its legacy of visionary leadership - Middle East Business News and Information
Dubai, United Arab Emirates: Takeda, a global, research and development-driven biopharmaceutical leader, has appointed Hernán Porcile as the new Area Head for its Eurasia[1], Middle East and Africa (EAMEA) region. Formerly General Manager of Takeda Mexico, Hernán Porcile assumed his new role on July 1, 2025, and is now based in Dubai, United Arab Emirates, from where he will lead the company's strategic developments and accelerate growth across the diverse region.
Hernán's appointment comes at a pivotal moment as Takeda intensifies its focus on advancing sustainable, value-based healthcare across the region. Building on the company's strong foundation, Hernán will deepen collaboration with key stakeholders, strengthen local systems, and drive innovation through scientific exchange and partnerships, further reinforcing Takeda's long-term commitment to resilient healthcare infrastructure and fostering a lasting impact.
'The EAMEA region's rapidly evolving healthcare landscape presents tremendous opportunities for Takeda, particularly as key markets in the region pursue bold national visions. As a purpose-driven, patient-centric company, we are proud to contribute to these transformative efforts by advancing access to innovative and high-quality healthcare solutions. The region remains a strategic growth priority for Takeda, as we continue to invest in sustainable healthcare solutions and deepen our presence across key markets,' said Hernán Porcile, Takeda's newly appointed EAMEA Area Head.
Hernán joined Takeda in 2009 as Administration and Finance Director in Argentina and has since held several leadership roles, including serving as Head of Takeda Mexico and Colombia. He has also overseen operations across Latin America, covering the Southern Cone, Andean Region, Mexico, and Central America. Throughout his career, he has led key transformation initiatives and strategic projects, with expertise spanning finance, commercial development, and gastroenterology. Notably, he oversaw the successful launch of three critical therapies aimed at improving outcomes for patients with multiple myeloma, hereditary angioedema, and inflammatory bowel disease.
Prior to joining Takeda, he spent over 12 years at Schering-Plough. Hernán also serves as Secretary of the Mexican Association of Pharmaceutical Research Industries (AMIIF), where he leads the Clinical Research Commission. He holds a degree in Public Accounting from the University of Morón in Argentina and an MBA in Strategy from the University of Belgrano.
With deep expertise in emerging markets and a strong track record of transformational leadership, Hernán is poised to play a pivotal role in advancing Takeda's mission to deliver better health and a brighter future to patients across the Eurasia, Middle East and Africa area. [1] Takeda's Eurasia region is defined to include Türkiye, Kazakhstan, Azerbaijan, and Ukraine.
About Takeda:
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience
and vaccines. Together with our partners, we aim to improve patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mid East Info
23-07-2025
- Mid East Info
Takeda appoints Hernán Porcile as Head of the EAMEA region, continuing its legacy of visionary leadership - Middle East Business News and Information
From his new base in Dubai, a key international gateway, Hernán will steer Takeda's strategic priorities across diverse, fast-growing EAMEA (Eurasia, the Middle East, and Africa) markets Dubai, United Arab Emirates: Takeda, a global, research and development-driven biopharmaceutical leader, has appointed Hernán Porcile as the new Area Head for its Eurasia[1], Middle East and Africa (EAMEA) region. Formerly General Manager of Takeda Mexico, Hernán Porcile assumed his new role on July 1, 2025, and is now based in Dubai, United Arab Emirates, from where he will lead the company's strategic developments and accelerate growth across the diverse region. Hernán's appointment comes at a pivotal moment as Takeda intensifies its focus on advancing sustainable, value-based healthcare across the region. Building on the company's strong foundation, Hernán will deepen collaboration with key stakeholders, strengthen local systems, and drive innovation through scientific exchange and partnerships, further reinforcing Takeda's long-term commitment to resilient healthcare infrastructure and fostering a lasting impact. 'The EAMEA region's rapidly evolving healthcare landscape presents tremendous opportunities for Takeda, particularly as key markets in the region pursue bold national visions. As a purpose-driven, patient-centric company, we are proud to contribute to these transformative efforts by advancing access to innovative and high-quality healthcare solutions. The region remains a strategic growth priority for Takeda, as we continue to invest in sustainable healthcare solutions and deepen our presence across key markets,' said Hernán Porcile, Takeda's newly appointed EAMEA Area Head. Hernán joined Takeda in 2009 as Administration and Finance Director in Argentina and has since held several leadership roles, including serving as Head of Takeda Mexico and Colombia. He has also overseen operations across Latin America, covering the Southern Cone, Andean Region, Mexico, and Central America. Throughout his career, he has led key transformation initiatives and strategic projects, with expertise spanning finance, commercial development, and gastroenterology. Notably, he oversaw the successful launch of three critical therapies aimed at improving outcomes for patients with multiple myeloma, hereditary angioedema, and inflammatory bowel disease. Prior to joining Takeda, he spent over 12 years at Schering-Plough. Hernán also serves as Secretary of the Mexican Association of Pharmaceutical Research Industries (AMIIF), where he leads the Clinical Research Commission. He holds a degree in Public Accounting from the University of Morón in Argentina and an MBA in Strategy from the University of Belgrano. With deep expertise in emerging markets and a strong track record of transformational leadership, Hernán is poised to play a pivotal role in advancing Takeda's mission to deliver better health and a brighter future to patients across the Eurasia, Middle East and Africa area. [1] Takeda's Eurasia region is defined to include Türkiye, Kazakhstan, Azerbaijan, and Ukraine. About Takeda: Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.
Mid East Info
23-12-2024
- Mid East Info
Takeda Enhances Patient Care for Rare Genetic Disorder in the UAE and Beyond - Middle East Business News and Information
Takeda Enhances Patient Care for Rare Genetic Disorder in the UAE and Beyond Global biopharmaceutical leader Takeda successfully hosted event focused on improving HAE patient diagnosis and treatment Dubai, United Arab Emirates, December 23, 2024: Global biopharmaceutical company Takeda recently hosted the event 'Innovation and Hope: Connecting Minds to Transform HAE Patient Care' in the region, uniting healthcare professionals to discuss innovative therapies and collaborative strategies for managing Hereditary Angioedema (HAE) in the Middle East. Hereditary Angioedema (HAE) is a rare genetic disorder affecting approximately 1 in 50,000 individuals worldwide. It is characterized by recurrent episodes of swelling in various parts of the body, including the face, neck, and throat. Symptoms can be unpredictable and may occur at any age and swelling of the upper airways can be particularly dangerous and may lead to fatal asphyxiation. HAE attacks can last up to 5 days and may spread to another location before resolving, and can be triggered by factors such as stress, injuries, hormonal changes, and dental procedures. Symptoms typically worsen over the first 24 hours and subside over the next 48–72 hours. These unpredictable symptoms can lead to severe complications, making timely diagnosis and treatment crucial.[1] To address the gaps in HAE diagnosis and treatment in the UAE, this event showcased leading HAE healthcare experts from the region through a series of plenary sessions and panel discussions. These sessions raised awareness of both the clinical and societal dimensions of HAE care. It primarily focused on the nuances of local healthcare systems and diagnosis and treatment protocols, while also presenting the latest real-world case studies, clinical findings, and research to improve the lives of HAE patients. 'We take pride in bringing together healthcare professionals and patient advocates for 'Innovation and Hope: Connecting Minds to Transform HAE Patient Care'. It highlighted our commitment to enhancing the diagnosis and treatment of Hereditary Angioedema in the UAE. Through fostering collaboration and sharing advancements in care, we aim to improve health outcomes for patients and their families,' said, Ahmed Fayed, General Manager, Takeda East Gulf and Levant Cluster Professor Mohamed Abuzakouk, Consultant in Clinical Immunology and Allergy and Chairman of the Gulf Academy Conference on Allergy and Clinical Immunology 2025, Abu Dhabi, UAE, stated, 'The management of Hereditary Angioedema continues to evolve with events like these, and the collaboration between healthcare professionals, researchers, and patient advocates is crucial for improving patient care. By embracing advanced treatment options, we are offering hope to patients and their families, enabling them to live healthier, more stable lives without the constant fear of debilitating attacks.' Takeda is dedicated to enhancing access to HAE treatments across the Middle East by fostering regional collaborations and implementing tailored patient care approaches. The emphasis will remain on both short-term and long-term strategies to ensure sustainable improvements in HAE management, ultimately benefiting patients and their families in the region. [1] Lumry WR. Am J Manag Care 2013;19: S103–S110 Zuraw et al. J Allergy Clin Immunol Pract. 2013; 1:458–67 Bowen T, et al. Ann Allergy Asthma Immunol. 2008;100(Suppl 2): S30–S40 Aygören-Pürsün E, et al. Orphanet J Rare Dis. 2018; 13:73 Lumry WR. Front Med. 2018; 5:22 Zuraw BL. N Engl J Med. 2008;359:1027–36 MacGinnitie AJ. Pediatr Allergy Immunol. 2014; 25:420–7 Banerji A, et al. Ann Allergy Asthma Immunol. 2013; 111:329–36
Daily News Egypt
28-11-2024
- Daily News Egypt
Takeda, Egypt Healthcare Authority gear towards establishing IPU for cancer care
During the 5th Annual Egypt Healthcare Authority Forum, held in the New Administrative Capital, Takeda Egypt, in collaboration with the Egypt Healthcare Authority, announced key developments toward establishing an Integrated Practice Unit (IPU) for oncology care in Egypt. This announcement follows the signing of a Memorandum of Understanding (MoU) in March of this year, formalizing the strategic partnership to enhance the healthcare system for oncology patients in Egypt. At the forum, the outcomes of the successful collaboration between the Egypt Healthcare Authority and Takeda Pharmaceuticals were shared, and Dr. Samy Khalil, General Manager of Takeda Egypt, was honored for his pioneering contributions to improving Egypt's healthcare system. The IPU is a multidisciplinary team dedicated to providing comprehensive care for oncology patients, adhering to global standards. Operating under unified management, the team will measure both outcomes and costs while sharing responsibility for patient results. The IPU is envisioned as a model for similar units to be established within the Healthcare Authority's facilities across Egypt's governorates. It will also focus on continuous training for healthcare providers to ensure specialized, effective patient care. The forum also highlighted a recent visit by representatives from The Christie NHS Foundation Trust, a leading cancer hospital within the UK's National Health Service (NHS), to the Ismailia Medical Complex, managed by the Egypt Healthcare Authority in Ismailia Governorate. The visit, which took place earlier in November as part of a broader collaboration between Egypt and the NHS, included a three-day workshop with 14 international experts, conducted both in-person and virtually, to train Egypt Healthcare Authority professionals. In his opening remarks, Ahmed El-Sobky, Chairperson of the Egypt Healthcare Authority and Supervisor General of the Universal Health Insurance Project, emphasized that the establishment of the Integrated Practice Unit (IPU) at the Ismailia Medical Complex represents a pioneering initiative for public-private sector integration. He explained that the unit serves as a sustainable and scalable model for cancer care within the Healthcare Authority's system. El-Sobky also highlighted the importance of the partnership with Takeda in developing the healthcare sector's infrastructure, enhancing oncology care standards, and supporting Egypt's Vision 2030 strategic goals. Professor Mark Saunders, Consultant Clinical Oncologist at The Christie NHS Foundation Trust, said: 'We hope our collaboration with NHS Global and the EHA on their Integrated Practice Unit initiative will contribute to a national uplift in cancer care within Egypt. The Christie NHS Foundation Trust has been involved in assessing and reviewing current cancer service delivery within the EHA healthcare system. We were greatly impressed by the enthusiasm and dedication of all attendees and noted their outstanding commitment to delivering the best possible patient-centered care.' Samy Khalil, General Manager of Takeda Egypt, expressed pride in the partnership with the Egypt Healthcare Authority, underscoring the role of public-private partnerships in enhancing the healthcare system in alignment with Egypt's Vision 2030. Khalil added that the collaboration includes developing training programs on the latest oncology treatments and establishing an Integrated Oncology Practice unit within the Healthcare Authority's facilities. He also acknowledged Stellar Consulting Solutions for their role in the successful execution of the project. The forum was attended by several prominent figures, including Amir Telwany, Executive Director of the Egypt Healthcare Authority, Hidenori Nishi, Chairman of the Japan Business Association, Shigeo Nishizawa, Managing Director of the Japan External Trade Organization (JETRO) in Egypt, Mamdouh Al-Arabi, Member of the Egyptian-Japanese Business Council, as well as representatives from the government and private sectors. This attendance underscores the significance of the partnership in enhancing Egypt's healthcare system. Through continued collaboration and advanced medical innovation, Takeda aims to improve public health, deliver exceptional medical care, and foster a positive, sustainable transformation within Egypt's healthcare sector.
